Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Bicalutamide
Drug ID BADD_D00271
Description Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Indications and Usage For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
Marketing Status approved
ATC Code L02BB03
DrugBank ID DB01128
KEGG ID D00961
MeSH ID C053541
PubChem ID 2375
TTD Drug ID D0V9BD
NDC Product Code 49711-1504; 49711-1509; 51846-1028; 62559-890; 71205-577; 0904-6019; 53104-7664; 16714-816; 60429-177; 62559-680; 43265-7195; 46014-1111; 82920-004; 54893-0001; 16729-023; 58623-0068; 63629-8308; 15308-0360; 47335-485
UNII A0Z3NAU9DP
Synonyms bicalutamide | 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide | Casodex | Cosudex | ICI-176334 | ICI 176334
Chemical Information
Molecular Formula C18H14F4N2O4S
CAS Registry Number 90357-06-5
SMILES CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hypocalcaemia14.04.01.0040.005905%
Hypochromic anaemia01.03.02.004--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.002812%
Hypokalaemia14.05.03.0020.004921%
Hypopituitarism05.03.02.0010.001406%
Ileus07.13.01.0010.002109%
Immune system disorder10.02.01.001--Not Available
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.011--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Influenza like illness08.01.03.010--
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.0010.005624%Not Available
Injection site induration12.07.03.007; 08.02.03.0070.004218%Not Available
Injection site mass08.02.03.009; 12.07.03.0100.003093%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.007733%Not Available
Injection site reaction12.07.03.015; 08.02.03.0140.003515%
Injection site ulcer08.02.03.016; 23.07.03.012; 12.07.03.0170.001406%Not Available
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.0330.052727%Not Available
Intestinal obstruction07.13.01.002--Not Available
Iron deficiency anaemia14.13.02.001; 01.03.01.002--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.006609%Not Available
Laboratory test abnormal13.18.01.001--Not Available
Leukaemia16.01.03.001; 01.10.03.0010.001406%
Leukopenia01.02.02.0010.002109%Not Available
Libido decreased21.03.02.005; 19.08.03.0010.001406%
Liver disorder09.01.08.0010.002109%Not Available
Liver function test abnormal13.03.04.030--Not Available
Logorrhoea19.19.02.001; 17.02.08.0060.001406%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 13 Pages